Skip to content
Artwork for Dementia Researcher Vodcast
ScienceBusinessCareersSocial Sciences

Dementia Researcher Vodcast

Dementia Researcher

A biweekly podcast for early career researchers, bringing together fantastic guests to discuss their research, careers + much more.

Dedicated to sharing the science, encouraging collaborations, attracting more people to the field of Alzheimer's and other dementias research, and supporting those already here to succeed.

Brought to you by https://www.dementiaresearcher.nihr.ac.uk at University College London, in association with Alzheimer's Association, Alzheimer's Research UK, Alzheimer's Society and Race Against Dementia - everything you need, all in one place. supporting early career researchers across the world

Register today to recieve weekly bulletins, with news, funding opportunities, jobs, and events.

Play
  • 25 episodes
  • fortnightly
  • Avg 49 min
  • English

Support the show

Goes straight to the publisher. podnod takes nothing.

Counted on this page — what you have heard stays on this device, so it is not something the list can be paged by.
  • #370
    November 6 · 52 min· Video

    Alzheimer Europe 2026 Conference Highlights - Part Two

    This episode of the Dementia Researcher Podcast comes from the final day of the 36th Alzheimer Europe Conference in Dublin, looking back over three days of research, policy and lived experience. Hosted by Dr Felicity Slocombe from the University of Bradford, the episode features Professor Andy Northcott from the Geller Institute of Ageing and Memory at the University of West London, Dr Gianna Kohl from UCL and Dr Tiffeny James from the University of Greenwich. The conversation starts before the conference itself, with an Interdem keynote on ethics in care. It challenged the idea of “therapeutic lying”, and the debate carried on over dinner. From there, the panel talks about psychosocial research taking the plenary stage and what blood biomarkers look like to two qualitative researchers who went along to learn. They also cover specialist seating that eases pain and agitation, and whether having “Alzheimer” in the name of most national dementia organisations helps or hinders people with other forms of dementia. How dementia language travels across cultures comes up too, as does whether the conference venue itself is dementia friendly. In this episode: Is lying ever therapeutic? Psychosocial research on the plenary stage Blood biomarkers for the rest of us Why seating matters in dementia care Does “Alzheimer” in a name help or hinder? Living alone, or caring from a distance Emergency care when the paramedic has to leave Lived experience moves from add-on to everyday -- A transcript of this show, links and show notes and profile on all our guests are available on our website at https://www.dementiaresearcher.nihr.ac.uk. If you prefer to watch rather than listen, you will find a video version of this podcast on Apple Podcasts, YouTube, and on our website. Leave us a tip: https://dementia-researcher.captivate.fm/support Follow us on social media: https://www.instagram.com/dementia_researcher/ https://www.facebook.com/Dementia.Researcher/ https://www.twitter.com/demrescommunity https://www.linkedin.com/company/dementia-researcher https://bsky.app/profile/dementiaresearcher.bsky.social Download and Register with our Community App: https://www.onelink.to/dementiaresearcher We gratefully acknowledge the support of our funders: Alzheimer’s Association, Race Against Dementia, Alzheimer’s Research UK, Alzheimer’s Society, and the National Institute for Health and Care Research. The views and opinions expressed by guests in this podcast are their own and do not necessarily reflect those of the producers, funders, or sponsors. Subscribe to our sister show 'Dementia Researcher The Blogs': https://podfollow.com/dementia-researcher-blogs

    • Chapters
  • #369
    November 6 · 30 min· Video

    Alzheimer Europe 2026 Conference Highlights - Part One

    This episode of the Dementia Researcher Podcast comes from the 36th Alzheimer Europe Conference in Dublin. Researchers, policymakers and people with lived experience met there under the theme “Sláinte: Building momentum in dementia through policy, research and partnership”. Hosted by Dr Jodi Watt from the University of Glasgow, the episode features Dr Rasa Mikelytė from the University of Kent, Dr Julieta Camino from the University of East Anglia and Dr Catherine Quinn from the University of Bradford. It was recorded at the end of the second day. There was far more going on than any one person could see, so the panel take turns sharing the sessions, posters and conversations that made them think. Many of their picks are about everyday parts of life with dementia that research can overlook, from the chairs people sit in all day to how farmers access services. Rights and identity come up throughout. People living with dementia spoke about the right to stay at home. There was discussion of the language we use about dementia. And LGBTQIA+ sessions made non-binary and trans experiences part of the conversation. Young onset dementia had more attention than the panel has seen before, and they reflect on the “A Day in My Life” plenary and what it showed about working carers. In this episode: Why being seen, heard and valued still needs saying How the right chair can change life in advanced dementia Who decides the language we use about dementia Making sure co-creation is more than a label Rights, from staying at home to deprivation of liberty Young onset dementia moves up the agenda LGBTQIA+ lives and the strength of belonging Where lived experience fits at Alzheimer Europe -- A transcript of this show, links and show notes and profile on all our guests are available on our website at https://www.dementiaresearcher.nihr.ac.uk. If you prefer to watch rather than listen, you will find a video version of this podcast on Apple Podcasts, YouTube, and on our website. Leave us a tip: https://dementia-researcher.captivate.fm/support Follow us on social media: https://www.instagram.com/dementia_researcher/ https://www.facebook.com/Dementia.Researcher/ https://www.twitter.com/demrescommunity https://www.linkedin.com/company/dementia-researcher https://bsky.app/profile/dementiaresearcher.bsky.social Download and Register with our Community App: https://www.onelink.to/dementiaresearcher We gratefully acknowledge the support of our funders: Alzheimer’s Association, Race Against Dementia, Alzheimer’s Research UK, Alzheimer’s Society, and the National Institute for Health and Care Research. The views and opinions expressed by guests in this podcast are their own and do not necessarily reflect those of the producers, funders, or sponsors. Subscribe to our sister show 'Dementia Researcher The Blogs': https://podfollow.com/dementia-researcher-blogs

    • Chapters
  • #368
    October 23 · 54 min· Video

    XXplored - Women's Heart Health and Dementia Risk

    In this episode of XXplored: Women's Brain Health, host Dr Laura Stankeviciute from the University of Gothenburg is joined by Dr Jenny Rabin from the University of Toronto and Sunnybrook Research Institute, and Dr Louise Schindler from King's College London, to explain why the heart and the brain belong in the same conversation for women. Cardiovascular disease is the leading cause of death for women worldwide, yet the picture most people hold of a heart attack is still an older man clutching his chest. The same blind spot carries over to the brain. Most of the dementia risk factors named by the 2024 Lancet Commission, from high blood pressure and LDL cholesterol to diabetes and smoking, are cardiovascular ones, and a growing body of evidence suggests several of them weigh more heavily on women than on men. Jenny Rabin, a neuropsychologist whose work began with vascular contributions to Alzheimer's disease, and Louise Schindler, whose PhD linked cardiometabolic health across the menopause years to later brain changes, follow that thread through a woman's life. In this episode: Why heart disease is the leading killer of women, and what that means for the brain The heart attack symptoms women are most likely to miss What vascular dementia really is, and why it rarely travels alone Why blood pressure in your 40s may matter more for women The female-specific risk factors missing from risk calculators What pregnancy complications can tell us decades later Hot flushes, HRT and the Women’s Health Initiative, revisited GLP-1s, menopause and the belly fat question -- A transcript of this show, links and show notes and profile on all our guests are available on our website at https://www.dementiaresearcher.nihr.ac.uk. If you prefer to watch rather than listen, you will find a video version of this podcast on Apple Podcasts, YouTube, and on our website. Leave us a tip: https://dementia-researcher.captivate.fm/support Follow us on social media: https://www.instagram.com/dementia_researcher/ https://www.facebook.com/Dementia.Researcher/ https://www.twitter.com/demrescommunity https://www.linkedin.com/company/dementia-researcher https://bsky.app/profile/dementiaresearcher.bsky.social Download and Register with our Community App: https://www.onelink.to/dementiaresearcher We gratefully acknowledge the support of our funders: Alzheimer’s Association, Race Against Dementia, Alzheimer’s Research UK, Alzheimer’s Society, and the National Institute for Health and Care Research. The views and opinions expressed by guests in this podcast are their own and do not necessarily reflect those of the producers, funders, or sponsors. Subscribe to our sister show 'Dementia Researcher The Blogs': https://podfollow.com/dementia-researcher-blogs

    • Transcript
    • Chapters
  • #368
    October 23 · 54 min· Video

    XXplored - Women's Cardiovascular Health

    In this episode of XXplored: Women's Brain Health, host Dr Laura Stankeviciute from the University of Gothenburg is joined by Dr Jenny Rabin from the University of Toronto and Sunnybrook Research Institute, and Dr Louise Schindler from King's College London, to explain why the heart and the brain belong in the same conversation for women. Cardiovascular disease is the leading cause of death for women worldwide, yet the picture most people hold of a heart attack is still an older man clutching his chest. The same blind spot carries over to the brain. Most of the dementia risk factors named by the 2024 Lancet Commission, from high blood pressure and LDL cholesterol to diabetes and smoking, are cardiovascular ones, and a growing body of evidence suggests several of them weigh more heavily on women than on men. Jenny Rabin, a neuropsychologist whose work began with vascular contributions to Alzheimer's disease, and Louise Schindler, whose PhD linked cardiometabolic health across the menopause years to later brain changes, follow that thread through a woman's life. In this episode: Why heart disease is the leading killer of women, and what that means for the brain The heart attack symptoms women are most likely to miss What vascular dementia really is, and why it rarely travels alone Why blood pressure in your 40s may matter more for women The female-specific risk factors missing from risk calculators What pregnancy complications can tell us decades later Hot flushes, HRT and the Women’s Health Initiative, revisited GLP-1s, menopause and the belly fat question -- A transcript of this show, links and show notes and profile on all our guests are available on our website at https://www.dementiaresearcher.nihr.ac.uk. If you prefer to watch rather than listen, you will find a video version of this podcast on Apple Podcasts, YouTube, and on our website. Leave us a tip: https://dementia-researcher.captivate.fm/support Follow us on social media: https://www.instagram.com/dementia_researcher/ https://www.facebook.com/Dementia.Researcher/ https://www.twitter.com/demrescommunity https://www.linkedin.com/company/dementia-researcher https://bsky.app/profile/dementiaresearcher.bsky.social Download and Register with our Community App: https://www.onelink.to/dementiaresearcher We gratefully acknowledge the support of our funders: Alzheimer’s Association, Race Against Dementia, Alzheimer’s Research UK, Alzheimer’s Society, and the National Institute for Health and Care Research. The views and opinions expressed by guests in this podcast are their own and do not necessarily reflect those of the producers, funders, or sponsors. Subscribe to our sister show 'Dementia Researcher The Blogs': https://podfollow.com/dementia-researcher-blogs

    • Transcript
    • Chapters
  • #367
    October 9 · 1 hr 11 min· Video

    Starting & Managing Academic Collaborations

    Academic collaborations shape most research careers, yet few researchers are ever taught how to start one, who to trust, or what needs agreeing before the work begins. Adam Smith is joined by Dr Sarah Marzi, Reader in Neurogenomics at the UK Dementia Research Institute at King's College London, and Professor Georgina Charlesworth, Professor of Clinical Psychology of Ageing and Dementia at UCL and joint lead of the SPIN-D Network+. Also joining are Professor Nathan Davies, Professor of Ageing and Applied Health and Care Research at Queen Mary University of London and co-director of the Alzheimer's Society Doctoral Training Centre for Integrated Dementia Care, and Dr Amanda Heslegrave, Principal Research Fellow at the UK DRI at UCL and co-lead of the UK DRI Biomarker Factory. Between them they run an international research partnership, a national network with around 35 named co-applicants, a doctoral training centre across five universities, and a shared biomarker platform working with research teams across many projects. The conversation follows a collaboration from first contact to final paper. It starts with how partnerships begin, often from a conference conversation or an email about data, and who should be on the application. It moves on to how to tell genuine collaboration from a request for a service, and how leadership, writing and credit are divided once the work is funded. The guests also talk about what happens when things go wrong, from partners who stop replying before a deadline to difficult meetings that leave early career researchers unsupported. Their experience points to the same conclusion. Collaborations work best when leadership, contribution, behaviour and authorship are discussed early and revisited as the work changes. In this episode: How good collaborations begin, often with an email, a conference talk or someone admitting they need help Who should be on a grant application, and how large networks decide who stays involved What to do when the people you approach are planning to lead the same bid How specialist labs and shared platforms tell genuine collaboration from a request for a service Who should write a multi-institution grant, and how to share leadership without duplicating every decision When to discuss authorship, and why it needs revisiting as contributions change How to handle collaborators who miss deadlines, go silent or will not approve a final draft Why agreed standards of behaviour protect early career researchers in collaborative and PPI meetings Essential links / resources mentioned in the show: Team EMERALD Dementia Frontiers Fund The 100-plus Study UK DRI Biomarker Factory SPIN-D Network+ INTERDEM Alzheimer's Society Doctoral Training Centre for Integrated Care UK DRI Biomarker Factory -- A transcript of this show, links and show notes and profile on all our guests are available on our website at https://www.dementiaresearcher.nihr.ac.uk. If you prefer to watch rather than listen, you will find a video version of this podcast on Apple Podcasts, YouTube, and on our website. Leave us a tip: https://dementia-researcher.captivate.fm/support Follow us on social media: https://www.instagram.com/dementia_researcher/ https://www.facebook.com/Dementia.Researcher/ https://www.twitter.com/demrescommunity https://www.linkedin.com/company/dementia-researcher https://bsky.app/profile/dementiaresearcher.bsky.social Download and Register with our Community App: https://www.onelink.to/dementiaresearcher We gratefully acknowledge the support of our funders: Alzheimer’s Association, Race Against Dementia, Alzheimer’s Research UK, Alzheimer’s Society, and the National Institute for Health and Care Research. The views and opinions expressed by guests in this podcast are their own and do not necessarily reflect those of the producers, funders, or sponsors. Subscribe to our sister show 'Dementia Researcher The Blogs': https://podfollow.com/dementia-researcher-blogs

    • Transcript
    • Chapters
  • #366
    September 20 · 55 min· Video

    Happy 200th: How UCL is Changing Dementia Research

    In this special episode, recorded to mark UCL's 200th birthday and released on World Alzheimer's Day, three UCL researchers working at very different ends of dementia research come together to talk about what the university has contributed, and where the field goes next. Professor Selina Wray hosts, joined by Dr Aygun Badalova, a neuropsychologist working on digital neurorehabilitation at the UCL Queen Square Institute of Neurology, Professor Tammaryn Lashley, Professor of Neuroscience and past president of the British Neuropathological Society, and Professor Andre Altmann, Professor of Biomedical Data Science and AI, who leads the COMBINE Lab. Their three approaches could hardly be further apart. Aygun works with people living with dementia and a therapy app built around photographs of the people who matter to them. Tammaryn works with donated post-mortem brain tissue and the pathology that no scan can yet see. Andre works with datasets large enough to assemble a disease timeline nobody has lived long enough to observe directly. The conversation moves between all three, taking in why no two brains with the same diagnosis look the same, what blood-based biomarkers can and cannot tell us yet, where non-drug interventions sit alongside the new anti-amyloid treatments, and what it actually takes to hold that breadth of work inside a single institution. This year's World Alzheimer's Month campaign is built around the idea that the earlier you know, the more you can do, and diagnosis runs through much of the discussion. Along the way there are some UCL landmarks worth knowing about, including the 23rd letter in a pile of replies to an Alzheimer's Society newsletter appeal and what it set in motion, Sea Hero Quest, the Lancet Commission's modifiable risk factors, the tau gene silencing trial, Insight 46, and the UK DRI. The episode closes on what each guest hopes we will find strange about dementia research by the time UCL turns 220. In this episode: What two hundred years of UCL has actually contributed to dementia research, told through three very different kinds of work rather than a roll call. Why each of the guests has stayed, and what their research would have lost elsewhere, from Queen Square Brain Bank and three thousand characterised brains to the Hawkes Institute sitting alongside the Dementia Research Centre. How the full pipeline in one institution changes the questions people ask, with cells, tissue and clinic from the same individual, and neurologists now bringing cases to the lab rather than the other way round. Where UCL has changed the field, including letter number 23 and the Jennings family, Sea Hero Quest, the Lancet Commission risk factors, TREM2, the tau gene silencing trial, Insight 46 and the UK DRI. Diagnosis as the theme of World Alzheimer's Day, and what still stands in the way, from co-pathologies that no blood test can yet see to deciding who is suited to the new treatments. What none of this can do inside one building, and why rare dementias, genetic risk and a therapy app all depend on people well beyond UCL. Why disease modification and support for people living with dementia today are answering different questions, and the case for funding both. What the guests want to look strange by UCL's 220th birthday, and what they are asking listeners to do now. -- A transcript of this show, links and show notes and profile on all our guests are available on our website at https://www.dementiaresearcher.nihr.ac.uk. If you prefer to watch rather than listen, you will find a video version of this podcast on Apple Podcasts, YouTube, and on our website. Leave us a tip: https://dementia-researcher.captivate.fm/support Follow us on social media: https://www.instagram.com/dementia_researcher/ https://www.facebook.com/Dementia.Researcher/ https://www.twitter.com/demrescommunity https://www.linkedin.com/company/dementia-researcher https://bsky.app/profile/dementiaresearcher.bsky.social Download and Register with our Community App: https://www.onelink.to/dementiaresearcher We gratefully acknowledge the support of our funders: Alzheimer’s Association, Race Against Dementia, Alzheimer’s Research UK, Alzheimer’s Society, and the National Institute for Health and Care Research. The views and opinions expressed by guests in this podcast are their own and do not necessarily reflect those of the producers, funders, or sponsors. Subscribe to our sister show 'Dementia Researcher The Blogs': https://podfollow.com/dementia-researcher-blogs

    • Chapters
  • #364
    September 11 · 1 hr 3 min· Video

    XXplored - Why Women's Sleep Is Different

    Sleep, the menstrual cycle and women's brain health rarely line up the way people expect. Women report worse sleep than men, yet objective recordings often show them sleeping longer and spending more time in deep sleep, and nobody has fully explained the gap. Host Dr Laura Stankeviciute, a postdoctoral researcher at the University of Gothenburg working on sleep and sex differences in brain ageing, is joined by Professor Christian Benedict, Professor of Pharmacology at Uppsala University and scientific spokesperson for the Swedish Sleep Research Society, and Dr Alana Brown, a postdoctoral fellow at the Rotman Research Institute at Baycrest, whose research looks at how ovarian hormone loss changes sleep and memory. The conversation moves from sleep architecture through the four phases of the menstrual cycle, into why insomnia is three times more common in women from puberty onwards and why obstructive sleep apnea is so often missed when the textbook symptoms were written from male patients. There is a straight assessment of melatonin, magnesium and creatine along the way, and a case for treating sleep as part of the treatment rather than a symptom that will sort itself out. Key takeaways The subjective and objective sleep paradox sits at the centre of the episode: women report worse sleep, but recordings often show longer total sleep time and more deep slow wave sleep than age-matched men. Longer REM sleep latency in older women is raised as a possible early marker of brain vulnerability, with links to amyloid-beta and phosphorylated tau build-up. Sleep does shift across the menstrual cycle, with the luteal phase most consistently linked to poorer sleep, but the guests push back on how certain social media makes this look. HRT can ease vasomotor symptoms without fixing sleep, because years of failed nights build a psychological pattern that needs unlearning through CBT for insomnia. Obstructive sleep apnea in women often presents without the loud snoring and witnessed apneas of the male picture, and prevalence climbs after menopause until the sex gap narrows. The episode argues sleep is a physiological need rather than a lifestyle factor, and belongs inside the intervention rather than being left to improve on its own. -- A transcript of this show, links and show notes and profile on all our guests are available on our website at https://www.dementiaresearcher.nihr.ac.uk. If you prefer to watch rather than listen, you will find a video version of this podcast on Apple Podcasts, YouTube, and on our website. Leave us a tip: https://dementia-researcher.captivate.fm/support Follow us on social media: https://www.instagram.com/dementia_researcher/ https://www.facebook.com/Dementia.Researcher/ https://www.twitter.com/demrescommunity https://www.linkedin.com/company/dementia-researcher https://bsky.app/profile/dementiaresearcher.bsky.social Download and Register with our Community App: https://www.onelink.to/dementiaresearcher We gratefully acknowledge the support of our funders: Alzheimer’s Association, Race Against Dementia, Alzheimer’s Research UK, Alzheimer’s Society, and the National Institute for Health and Care Research. The views and opinions expressed by guests in this podcast are their own and do not necessarily reflect those of the producers, funders, or sponsors. Subscribe to our sister show 'Dementia Researcher The Blogs': https://podfollow.com/dementia-researcher-blogs

    • Chapters
  • #363
    August 28 · 48 min· Video

    Fellowship vs Lectureship: Which Is Right for You?

    Should you pursue a fellowship or apply for a lectureship? The choice is often framed as protected research time versus a permanent contract, but the reality is more complicated. Dr Fiona McLean hosts Dr Warren Donnellan from University of Liverpool, Dr Kamar Ameen-Ali from Teesside University, and Dr Sarah-Naomi James from University College London, to compare the jobs as they are actually experienced. They discuss teaching, hidden administration, research independence, institutional support, pay, promotion and what happens when funding ends. They also ask whether any academic role can now be considered secure, and share the questions candidates should ask before accepting a post. Their routes show that fellowships and lectureships are not separate tracks: teaching can strengthen a fellow's next move, lecturers can still win fellowships, and careers rarely follow the tidy sequence shown on a CV. In this episode: What teaching-and-research and teaching-and-scholarship lectureships involve day to day How fellowships create independence, and where institutional control still applies Why teaching, administration and student support often consume more time than workload figures suggest What happens when a fellowship ends, including tenure-track promises and the need for further funding How salary bands, spine points and contribution points affect pay Whether any academic role can now be considered secure The interview questions that reveal expectations and departmental culture Why teaching experience, mentorship and resilience can keep more than one career route open -- A transcript of this show, links and show notes and profile on all our guests are available on our website at https://www.dementiaresearcher.nihr.ac.uk. If you prefer to watch rather than listen, you will find a video version of this podcast on Apple Podcasts, YouTube, and on our website. Leave us a tip: https://dementia-researcher.captivate.fm/support Follow us on social media: https://www.instagram.com/dementia_researcher/ https://www.facebook.com/Dementia.Researcher/ https://www.twitter.com/demrescommunity https://www.linkedin.com/company/dementia-researcher https://bsky.app/profile/dementiaresearcher.bsky.social Download and Register with our Community App: https://www.onelink.to/dementiaresearcher We gratefully acknowledge the support of our funders: Alzheimer’s Association, Race Against Dementia, Alzheimer’s Research UK, Alzheimer’s Society, and the National Institute for Health and Care Research. The views and opinions expressed by guests in this podcast are their own and do not necessarily reflect those of the producers, funders, or sponsors. Subscribe to our sister show 'Dementia Researcher The Blogs': https://podfollow.com/dementia-researcher-blogs

    • Chapters
  • #361
    August 14 · 47 min· Video

    Changing the Course of Dementia: What Will Make the Biggest Difference?

    Changing the course of dementia depends entirely on where you are standing, and this panel is standing in four different places. Recorded in front of a live audience at the Alzheimer's Research UK Thames Valley Network Dementia Research Day 2026, Professor Emma Mead, Chief Scientific Officer at the ARUK Oxford Drug Discovery Institute, puts the question to four people who see the problem from very different ends: Associate Professor Sanjay Manohar, computational neuroscientist and lead of the Cognitive Disorders Clinic at the John Radcliffe; Professor Michele Hu, consultant neurologist at Oxford, who runs the 1,600 person Oxford Discovery Parkinson's cohort; Associate Professor Laura Winchester, bioinformatician in Oxford's Department of Psychiatry; and Peter Johnson, head of service at Dementia Oxfordshire. They cover precision diagnosis, adaptive trial design, blood biomarkers, exercise and diet, digital monitoring at home, and what patients say frightens them most, plus audience questions on genetic testing and the biomarker gap. It closes with a quick fire round where four specialists name four different priorities, and not one of them is a drug. Key takeaways Of roughly 500 patients seen with Alzheimer's, only about 10 have typical Alzheimer's and nothing else. Everyone else carries a different combination, and that fingerprint matters now that treatments target specific molecules. Until this year, getting a biological diagnosis meant a lumbar puncture, so around 70% of patients never had one. Blood markers change who gets tested, and raise the harder question of what you tell people afterwards. Multi-arm multi-stage designs, borrowed from prostate cancer, run several treatment arms against one placebo group and force go or no go calls at 6 to 12 months. ACT-PD is doing it for Parkinson's. In the exenatide trial the placebo group improved over two years simply from being in a trial. Regular contact and something to aim at has a measurable effect you have to design around. Once the survival figure and the monitoring burden are explained, most patients conclude the new Alzheimer's therapies are not yet for them. What they ask for is quality of life, not longer decline. Asked what would make the biggest impact, the panel chose home digital monitoring, opening up trial data after studies close, AI as a support for thinking, and joined up hospital and community care. Not one of them named a drug. -- A transcript of this show, links and show notes and profile on all our guests are available on our website at https://www.dementiaresearcher.nihr.ac.uk. If you prefer to watch rather than listen, you will find a video version of this podcast on Apple Podcasts, YouTube, and on our website. Leave us a tip: https://dementia-researcher.captivate.fm/support Follow us on social media: https://www.instagram.com/dementia_researcher/ https://www.facebook.com/Dementia.Researcher/ https://www.twitter.com/demrescommunity https://www.linkedin.com/company/dementia-researcher https://bsky.app/profile/dementiaresearcher.bsky.social Download and Register with our Community App: https://www.onelink.to/dementiaresearcher We gratefully acknowledge the support of our funders: Alzheimer’s Association, Race Against Dementia, Alzheimer’s Research UK, Alzheimer’s Society, and the National Institute for Health and Care Research. The views and opinions expressed by guests in this podcast are their own and do not necessarily reflect those of the producers, funders, or sponsors. Subscribe to our sister show 'Dementia Researcher The Blogs': https://podfollow.com/dementia-researcher-blogs

    • Transcript
    • Chapters
  • #360
    July 31 · 1 hr 7 min· Video

    XXplored - The Neuroscience of Motherhood

    Around 80% of women worldwide will become mothers, and pregnancy triggers the largest hormonal shift the body will ever experience. So what does it do to the brain, and does any of it last? In this episode of XXplored, host Dr Laura Stankeviciute, University of Gothenburg is joined by Dr Magdalena Martínez-García, Scientific Director of Maternal Health at the Ann S. Bowers Women's Brain Health Initiative, University of California Santa Barbara, and Dr Laura Pritschet, an NIH funded postdoctoral scholar at the University of Pennsylvania who leads the Maternal Brain Mapping Project. They get into the hormonal cascade that drives the whole process, what those widely reported grey matter reductions actually mean, and how one volunteer scanned 26 times from IVF to two years postpartum filled in the gap between before and after. They also take on baby brain, whether repeat pregnancies stack up in the brain, what the UK Biobank data hints at for later life dementia risk, the near total absence of miscarriage and stillbirth from this research, and where postpartum care falls short. Both guests are living through matrescence themselves while studying it, and they talk openly about what that has been like. Key takeaways Pregnancy brings hormone surges into the hundreds and thousandfold, far beyond anything seen across the menstrual cycle, and sensitivity to those shifts matters more than the absolute levels. Grey matter reductions across pregnancy are among the most replicable findings in neuroscience, and larger reductions are linked to stronger postpartum bonding rather than damage. Follow-up work found some of those changes still present six years after birth, suggesting they may be long-lasting or permanent. A second pregnancy produces the same pattern of change but less pronounced, and UK Biobank data suggests a trace of parity in the brain that levels off around four or five births. Baby brain gets reframed rather than dismissed: subjective reports are real, objective differences are slight and temporary, and increased cognitive load may carry later advantages. Miscarriage, stillbirth and abortion are almost entirely missing from maternal brain research, and both guests believe those women would be among the most motivated participants. Research now treats the perinatal period as a neurological transition, but healthcare has not caught up, with a single six week check standing in for what should be ongoing postpartum care. -- A transcript of this show, links and show notes and profile on all our guests are available on our website at https://www.dementiaresearcher.nihr.ac.uk. If you prefer to watch rather than listen, you will find a video version of this podcast on Apple Podcasts, YouTube, and on our website. Leave us a tip: https://dementia-researcher.captivate.fm/support Follow us on social media: https://www.instagram.com/dementia_researcher/ https://www.facebook.com/Dementia.Researcher/ https://www.twitter.com/demrescommunity https://www.linkedin.com/company/dementia-researcher https://bsky.app/profile/dementiaresearcher.bsky.social Download and Register with our Community App: https://www.onelink.to/dementiaresearcher We gratefully acknowledge the support of our funders: Alzheimer’s Association, Race Against Dementia, Alzheimer’s Research UK, Alzheimer’s Society, and the National Institute for Health and Care Research. The views and opinions expressed by guests in this podcast are their own and do not necessarily reflect those of the producers, funders, or sponsors. Subscribe to our sister show 'Dementia Researcher The Blogs': https://podfollow.com/dementia-researcher-blogs

    • Chapters
  • #359
    July 20 · 1 hr· Video

    AAIC Day Four 2026 Highlights

    In this episode, we share highlights from the fourth day of the 2026 Alzheimer’s Association International Conference (AAIC). Adam Smith chats with Dr Niying Li, Assistant Professor at the University of Georgia; Dr Natasha Anita, a Research Fellow at Harvard Medical School and Massachusetts General Hospital; and Lillian Morgado, Research Coordinator at Georgia State University. The AAIC brings together researchers from all areas of research to share their work, theories and breakthroughs while exploring opportunities to accelerate work and elevate careers. Key topics The practical barriers to delivering new anti-amyloid treatments Rural and international inequalities in access to diagnosis and care What p-tau217 could tell us about future cognitive decline Promising results from new tau-targeting therapies Behavioural and personality changes as possible early signs of neurodegeneration Women’s brain health, inflammation and Alzheimer’s risk The ethical and legal questions surrounding biomarker disclosure Why research must include more countries and underrepresented populations Find out more about the conference at https://aaic.alz.org/ and on social media with #AAIC26 -- A transcript of this show, links and show notes and profile on all our guests are available on our website at https://www.dementiaresearcher.nihr.ac.uk. If you prefer to watch rather than listen, you will find a video version of this podcast on Apple Podcasts, YouTube, and on our website. Leave us a tip: https://dementia-researcher.captivate.fm/support Follow us on social media: https://www.instagram.com/dementia_researcher/ https://www.facebook.com/Dementia.Researcher/ https://www.twitter.com/demrescommunity https://www.linkedin.com/company/dementia-researcher https://bsky.app/profile/dementiaresearcher.bsky.social Download and Register with our Community App: https://www.onelink.to/dementiaresearcher We gratefully acknowledge the support of our funders: Alzheimer’s Association, Race Against Dementia, Alzheimer’s Research UK, Alzheimer’s Society, and the National Institute for Health and Care Research. The views and opinions expressed by guests in this podcast are their own and do not necessarily reflect those of the producers, funders, or sponsors. Subscribe to our sister show 'Dementia Researcher The Blogs': https://podfollow.com/dementia-researcher-blogs

  • #358
    July 15 · 45 min· Video

    AAIC Day Three 2026 Highlights

    In this episode, we share highlights from the third day of the 2026 Alzheimer’s Association International Conference (AAIC). Adam Smith chats with Cari Randa-Beaulieu, Provincial Coordinator, Knowledge Mobilization at the Alzheimer Society of British Columbia and Yukon; and Abrar AbuHamdia, a PhD candidate at Hamad Bin Khalifa University in Qatar. The AAIC brings together researchers from all areas of research to share their work, theories and breakthroughs while exploring opportunities to accelerate work and elevate careers. Key topics Alzheimer's disease subtypes and precision medicine Biomarkers and diagnostic accuracy in dementia Microglia and neuroinflammation therapies Global efforts in brain health promotion Co-design and lived experience in research Find out more about the conference at https://aaic.alz.org/ and on social media with #AAIC26 Note: We apologise for issues with the sound quality in the first part of this recording. -- A transcript of this show, links and show notes and profile on all our guests are available on our website at https://www.dementiaresearcher.nihr.ac.uk. If you prefer to watch rather than listen, you will find a video version of this podcast on Apple Podcasts, YouTube, and on our website. Leave us a tip: https://dementia-researcher.captivate.fm/support Follow us on social media: https://www.instagram.com/dementia_researcher/ https://www.facebook.com/Dementia.Researcher/ https://www.twitter.com/demrescommunity https://www.linkedin.com/company/dementia-researcher https://bsky.app/profile/dementiaresearcher.bsky.social Download and Register with our Community App: https://www.onelink.to/dementiaresearcher We gratefully acknowledge the support of our funders: Alzheimer’s Association, Race Against Dementia, Alzheimer’s Research UK, Alzheimer’s Society, and the National Institute for Health and Care Research. The views and opinions expressed by guests in this podcast are their own and do not necessarily reflect those of the producers, funders, or sponsors. Subscribe to our sister show 'Dementia Researcher The Blogs': https://podfollow.com/dementia-researcher-blogs

    • Chapters
  • #357
    July 13 · 53 min· Video

    AAIC Day Two 2026 Highlights

    In this episode, we share highlights from the second day of the 2026 Alzheimer’s Association International Conference (AAIC). Adam Smith chats with Nathania from Universitas Airlangga in Indonesia, Dr Arezoo Talebzadeh from Ghent University in Belgium, and Dr Suelyn Koerich from the University of Texas Health Science Center at Houston The AAIC brings together researchers from all areas of research to share their work, theories and breakthroughs while exploring opportunities to accelerate work and elevate careers. Key topics Anti-amyloid immunotherapies and personalized medicine Cultural sensitivity in dementia assessment The role of environment and architecture in dementia care Neuroinflammation and neuroprotective factors Biomarker validation and minimally invasive testing Impact of social determinants on dementia risk Soundscape and sensory health in dementia management Find out more about the conference at https://aaic.alz.org/ and on social media with #AAIC26 -- A transcript of this show, links and show notes and profile on all our guests are available on our website at https://www.dementiaresearcher.nihr.ac.uk. If you prefer to watch rather than listen, you will find a video version of this podcast on Apple Podcasts, YouTube, and on our website. Leave us a tip: https://dementia-researcher.captivate.fm/support Follow us on social media: https://www.instagram.com/dementia_researcher/ https://www.facebook.com/Dementia.Researcher/ https://www.twitter.com/demrescommunity https://www.linkedin.com/company/dementia-researcher https://bsky.app/profile/dementiaresearcher.bsky.social Download and Register with our Community App: https://www.onelink.to/dementiaresearcher We gratefully acknowledge the support of our funders: Alzheimer’s Association, Race Against Dementia, Alzheimer’s Research UK, Alzheimer’s Society, and the National Institute for Health and Care Research. The views and opinions expressed by guests in this podcast are their own and do not necessarily reflect those of the producers, funders, or sponsors. Subscribe to our sister show 'Dementia Researcher The Blogs': https://podfollow.com/dementia-researcher-blogs

    • Chapters
  • #356
    July 13 · 49 min· Video

    AAIC Day One 2026 Highlights

    In this episode, we share highlights from the first day of the 2026 Alzheimer’s Association International Conference (AAIC). Adam Smith chats with Sarah Graef from Rush University Medical Center and Muthia Huda Islami from the National Brain Centre Hospital Mahar Mardjono in Jakarta. The AAIC brings together researchers from all areas of research to share their work, theories and breakthroughs while exploring opportunities to accelerate work and elevate careers. Key topics Biomarkers for Alzheimer's disease Genetic epidemiology in diverse populations Lifestyle interventions and dementia prevention Innovative drug delivery methods for neurodegenerative diseases Global research collaborations and underrepresented populations Find out more about the conference at https://aaic.alz.org/ and on social media with #AAIC26 -- A transcript of this show, links and show notes and profile on all our guests are available on our website at https://www.dementiaresearcher.nihr.ac.uk. If you prefer to watch rather than listen, you will find a video version of this podcast on Apple Podcasts, YouTube, and on our website. Leave us a tip: https://dementia-researcher.captivate.fm/support Follow us on social media: https://www.instagram.com/dementia_researcher/ https://www.facebook.com/Dementia.Researcher/ https://www.twitter.com/demrescommunity https://www.linkedin.com/company/dementia-researcher https://bsky.app/profile/dementiaresearcher.bsky.social Download and Register with our Community App: https://www.onelink.to/dementiaresearcher We gratefully acknowledge the support of our funders: Alzheimer’s Association, Race Against Dementia, Alzheimer’s Research UK, Alzheimer’s Society, and the National Institute for Health and Care Research. The views and opinions expressed by guests in this podcast are their own and do not necessarily reflect those of the producers, funders, or sponsors. Subscribe to our sister show 'Dementia Researcher The Blogs': https://podfollow.com/dementia-researcher-blogs

  • #354
    July 4 · 33 min· Video

    Relay Podcast - Clinical Trials Advancement and Methods PIA 2026

    Welcome to the seventh season of the Dementia Researcher X ISTAART PIA Relay Podcast. Across six episodes, leading early career and senior researchers hand the mic from one ISTAART PIA to the next, giving you an honest, peer-to-peer tour of where dementia research is actually heading, from wearables and biomarkers to policy and trial design, in the run-up to AAIC. Series closer, and the relay comes full circle: Carla Abdelnour, who hosted episode one, returns as the guest. Carla is a clinician scientist in Barcelona and incoming Chair of the ISTAART Clinical Trials Advancement and Methods PIA, working on mixed neurodegenerative disease, particularly Lewy body and Alzheimer's pathology together. With host Sindhuja Tirumalai Govindarajan she explains why co-pathology is so common and what it means for treatment: does someone with both alpha-synuclein and Alzheimer's pathology respond to an anti-amyloid drug the same way as someone without? They discuss why she leans on fluid biomarkers, the wish for a synuclein PET tracer, and how trials might stratify or include people by co-pathology. Carla makes a useful point for anyone designing research, that clinical trial methods translate straight to observational studies, and previews the CTAM PIA's AAIC programme, including a panel and featured session on global representation in trials. Takeaways Mixed pathology is common, and co-occurring alpha-synuclein and Alzheimer's pathology may change how people respond to treatment. Trials could stratify or include people by co-pathology, but alpha-synuclein is currently detectable only in CSF, which limits that. Fluid biomarkers offer the specificity to track different proteinopathies and, potentially, response to treatment. Clinical trial design transfers straight to observational research: the same inclusion criteria, outcomes and sample-size thinking. Global representation in trials is a live priority, with a CTAM panel launching at AAIC. -- The Alzheimer’s Association International Society to Advance Alzheimer’s Research and Treatment (ISTAART) convenes the global Alzheimer’s and dementia science community. Members share knowledge, fuel collaboration and advance research to find more effective ways to detect, treat and prevent Alzheimer’s and other dementias. Professional Interest Areas (PIA) are an assembly of ISTAART members with common subspecialties or interests. There are currently 30 PIAs covering a wide range of interests and fields, from Neuroimaging to Diversity and Disparities and everything in between. Find out more at https://istaart.alz.org/ -- A transcript of this show, links and show notes and profile on all our guests are available on our website at https://www.dementiaresearcher.nihr.ac.uk. If you prefer to watch rather than listen, you will find a video version of this podcast on Apple Podcasts, YouTube, and on our website. Leave us a tip: https://dementia-researcher.captivate.fm/support Follow us on social media: https://www.instagram.com/dementia_researcher/ https://www.facebook.com/Dementia.Researcher/ https://www.twitter.com/demrescommunity https://www.linkedin.com/company/dementia-researcher https://bsky.app/profile/dementiaresearcher.bsky.social Download and Register with our Community App: https://www.onelink.to/dementiaresearcher We gratefully acknowledge the support of our funders: Alzheimer’s Association, Race Against Dementia, Alzheimer’s Research UK, Alzheimer’s Society, and the National Institute for Health and Care Research. The views and opinions expressed by guests in this podcast are their own and do not necessarily reflect those of the producers, funders, or sponsors. Subscribe to our sister show 'Dementia Researcher The Blogs': https://podfollow.com/dementia-researcher-blogs

    • Transcript
    • Chapters
  • #352
    July 3 · 33 min· Video

    Relay Podcast - PIA to Elevate Early Career Researchers

    Welcome to the seventh season of the Dementia Researcher X ISTAART PIA Relay Podcast. Across six episodes, leading early career and senior researchers hand the mic from one ISTAART PIA to the next, giving you an honest, peer-to-peer tour of where dementia research is actually heading, from wearables and biomarkers to policy and trial design, in the run-up to AAIC. Most people with hypertension after 50 never develop dementia, so what separates those who do? That is the question driving Dr Sindhuja Tirumalai Govindarajan, a neuroimaging researcher and outgoing Chair of the ISTAART PEERs PIA, recorded as she moves from a postdoc at the University of Pennsylvania to an assistant professorship at the Karolinska Institute. With host Dr Joe Kane she explains how machine learning on tens of thousands of MRI scans can pick up subtle brain changes years before symptoms, and why scans from different scanners have to be harmonised first. The conversation then turns to PEERs itself, a PIA built not around one research area but around early career researchers everywhere, and the work of levelling opportunity across borders through local routes like Neuroscience Next, WYLD and INTERDEM Academy. Sindhuja runs through the PIA's AAIC workshops, from narrative CVs to social bingo for ECRs, and closes with practical advice on getting people involved: make the ask specific. Takeaways Machine learning on large MRI datasets can detect brain changes years before any cognitive symptoms show. Scans from different scanners must be harmonised first, stripping out machine noise so only the biology remains. PEERs exists to level opportunity for early career researchers wherever they are, across every research area. Local routes such as Neuroscience Next, WYLD and INTERDEM Academy widen access for those who cannot get to the big conference. Interest among ECRs is common but clarity often is not, so make the ask specific and people will step up. -- The Alzheimer’s Association International Society to Advance Alzheimer’s Research and Treatment (ISTAART) convenes the global Alzheimer’s and dementia science community. Members share knowledge, fuel collaboration and advance research to find more effective ways to detect, treat and prevent Alzheimer’s and other dementias. Professional Interest Areas (PIA) are an assembly of ISTAART members with common subspecialties or interests. There are currently 30 PIAs covering a wide range of interests and fields, from Neuroimaging to Diversity and Disparities and everything in between. Find out more at https://istaart.alz.org/ -- A transcript of this show, links and show notes and profile on all our guests are available on our website at https://www.dementiaresearcher.nihr.ac.uk. If you prefer to watch rather than listen, you will find a video version of this podcast on Apple Podcasts, YouTube, and on our website. Leave us a tip: https://dementia-researcher.captivate.fm/support Follow us on social media: https://www.instagram.com/dementia_researcher/ https://www.facebook.com/Dementia.Researcher/ https://www.twitter.com/demrescommunity https://www.linkedin.com/company/dementia-researcher https://bsky.app/profile/dementiaresearcher.bsky.social Download and Register with our Community App: https://www.onelink.to/dementiaresearcher We gratefully acknowledge the support of our funders: Alzheimer’s Association, Race Against Dementia, Alzheimer’s Research UK, Alzheimer’s Society, and the National Institute for Health and Care Research. The views and opinions expressed by guests in this podcast are their own and do not necessarily reflect those of the producers, funders, or sponsors. Subscribe to our sister show 'Dementia Researcher The Blogs': https://podfollow.com/dementia-researcher-blogs

    • Transcript
    • Chapters
  • #350
    July 2 · 36 min· Video

    Relay Podcast - Lewy Body Dementias PIA

    Welcome to the seventh season of the Dementia Researcher X ISTAART PIA Relay Podcast. Across six episodes, leading early career and senior researchers hand the mic from one ISTAART PIA to the next, giving you an honest, peer-to-peer tour of where dementia research is actually heading, from wearables and biomarkers to policy and trial design, in the run-up to AAIC. Lewy body pathology shows up in roughly 30% of the brains of people who had dementia, yet it gets diagnosed in only about 5% of cases. Closing that gap has shaped much of Dr Joe Kane's career. Joe is a geriatric psychiatrist at Queen's University Belfast and outgoing Chair of the ISTAART Lewy Body Dementias PIA, and with host Dr Patrick Lao he traces his work from the Diamond Lewy programme to consensus diagnostic guidelines built by Delphi process. They discuss the symptoms clinicians often miss because they don't think to ask, from constipation to loss of smell, the cardiac scans and seed amplification assays now detecting pathology in CSF and even skin, and the TOP HAT trial repurposing an anti-sickness drug for hallucinations. Joe makes the case for a Lewy body specific rating scale, explains why the prodrome may be psychiatric or delirium rather than cognitive, and runs through the PIA's biggest AAIC programme in years, including a PIA Day panel on seed amplification assays. Takeaways Lewy body dementia is heavily underdiagnosed: pathology appears in about 30% of brains but is diagnosed in around 5%. Much of the disease shows outside the brain, in constipation, blood pressure and smell, so it gets missed if nobody asks. Seed amplification assays, now usable on CSF and even a small skin biopsy, are changing how the pathology is detected. Trials can fail on the wrong yardstick, which is why the PIA is building a Lewy body specific rating scale. The prodrome is not only cognitive; the first sign can be depression, psychosis or delirium, and those gaps need data. -- The Alzheimer’s Association International Society to Advance Alzheimer’s Research and Treatment (ISTAART) convenes the global Alzheimer’s and dementia science community. Members share knowledge, fuel collaboration and advance research to find more effective ways to detect, treat and prevent Alzheimer’s and other dementias. Professional Interest Areas (PIA) are an assembly of ISTAART members with common subspecialties or interests. There are currently 30 PIAs covering a wide range of interests and fields, from Neuroimaging to Diversity and Disparities and everything in between. Find out more at https://istaart.alz.org/ -- A transcript of this show, links and show notes and profile on all our guests are available on our website at https://www.dementiaresearcher.nihr.ac.uk. If you prefer to watch rather than listen, you will find a video version of this podcast on Apple Podcasts, YouTube, and on our website. Leave us a tip: https://dementia-researcher.captivate.fm/support Follow us on social media: https://www.instagram.com/dementia_researcher/ https://www.facebook.com/Dementia.Researcher/ https://www.twitter.com/demrescommunity https://www.linkedin.com/company/dementia-researcher https://bsky.app/profile/dementiaresearcher.bsky.social Download and Register with our Community App: https://www.onelink.to/dementiaresearcher We gratefully acknowledge the support of our funders: Alzheimer’s Association, Race Against Dementia, Alzheimer’s Research UK, Alzheimer’s Society, and the National Institute for Health and Care Research. The views and opinions expressed by guests in this podcast are their own and do not necessarily reflect those of the producers, funders, or sponsors. Subscribe to our sister show 'Dementia Researcher The Blogs': https://podfollow.com/dementia-researcher-blogs

    • Transcript
    • Chapters
  • #348
    July 1 · 32 min· Video

    Relay Podcast - Down Syndrome and Alzheimer's Disease PIA

    Welcome to the seventh season of the Dementia Researcher X ISTAART PIA Relay Podcast. Across six episodes, leading early career and senior researchers hand the mic from one ISTAART PIA to the next, giving you an honest, peer-to-peer tour of where dementia research is actually heading, from wearables and biomarkers to policy and trial design, in the run-up to AAIC. Almost everyone born with Down syndrome overproduces the amyloid precursor protein from birth, which makes it one of the clearest natural windows we have into how Alzheimer's begins. Dr Patrick Lao, Assistant Professor at Columbia and Programmes Chair of the ISTAART Down Syndrome and Alzheimer's Disease PIA, comes from a medical physics background and uses multimodal neuroimaging to map the disease across its genetic and sporadic forms. With host Lillian Morgado, he explains amyloid and tau PET, Thal phases and Braak staging, and how chronological age can stand in for disease stage in this population, with a typical symptom onset around 54. They talk about why people with Down syndrome were long left out of anti-amyloid trials and how that is now changing, and the risk and resilience research asking why some people fall off the expected timeline. Patrick also previews the PIA's AAIC PIA Day session on returning results, plus the separate DSAD/ADAD conference coming to London next year. Takeaways Genetic forms of Alzheimer's, including Down syndrome, let researchers study the earliest disease pathways before symptoms appear. In Down syndrome, chronological age can approximate disease stage, with symptoms typically expected around age 54. Imaging shows where amyloid and tau sit in the brain, the spatial detail a blood test cannot give. People with Down syndrome were historically excluded from anti-amyloid trials; that is shifting, with a lecanemab safety extension now underway. Not everyone follows the population timeline, and risk and resilience work asks what pushes onset earlier or later. -- The Alzheimer’s Association International Society to Advance Alzheimer’s Research and Treatment (ISTAART) convenes the global Alzheimer’s and dementia science community. Members share knowledge, fuel collaboration and advance research to find more effective ways to detect, treat and prevent Alzheimer’s and other dementias. Professional Interest Areas (PIA) are an assembly of ISTAART members with common subspecialties or interests. There are currently 30 PIAs covering a wide range of interests and fields, from Neuroimaging to Diversity and Disparities and everything in between. Find out more at https://istaart.alz.org/ -- A transcript of this show, links and show notes and profile on all our guests are available on our website at https://www.dementiaresearcher.nihr.ac.uk. If you prefer to watch rather than listen, you will find a video version of this podcast on Apple Podcasts, YouTube, and on our website. Leave us a tip: https://dementia-researcher.captivate.fm/support Follow us on social media: https://www.instagram.com/dementia_researcher/ https://www.facebook.com/Dementia.Researcher/ https://www.twitter.com/demrescommunity https://www.linkedin.com/company/dementia-researcher https://bsky.app/profile/dementiaresearcher.bsky.social Download and Register with our Community App: https://www.onelink.to/dementiaresearcher We gratefully acknowledge the support of our funders: Alzheimer’s Association, Race Against Dementia, Alzheimer’s Research UK, Alzheimer’s Society, and the National Institute for Health and Care Research. The views and opinions expressed by guests in this podcast are their own and do not necessarily reflect those of the producers, funders, or sponsors. Subscribe to our sister show 'Dementia Researcher The Blogs': https://podfollow.com/dementia-researcher-blogs

    • Transcript
    • Chapters
  • #346
    June 30 · 28 min· Video

    Relay Podcast - Health Policy PIA

    Welcome to the seventh season of the Dementia Researcher X ISTAART PIA Relay Podcast. Across six episodes, leading early career and senior researchers hand the mic from one ISTAART PIA to the next, giving you an honest, peer-to-peer tour of where dementia research is actually heading, from wearables and biomarkers to policy and trial design, in the run-up to AAIC. If we cured Alzheimer's tomorrow but did no work on cost, distribution or access, we would have cured it only for the richest people in the world. That line from Lillian Morgado sits at the centre of this episode. Lillian is a research coordinator at Georgia State University and Communications Chair of the ISTAART Health Policy PIA, working mainly in qualitative research and legal epidemiology. With host Dr Vanessa Young, she talks through what qualitative work actually involves, her research on caregivers and people with dementia in the justice system, and the question that opened up next: what happens to someone with no caregiver to advocate for them. They get into why AI and blood-based biomarkers are as much policy problems as scientific ones, how regulation differs across borders, and why policy is the bridge that decides whether science reaches the people it was meant for. Lillian also runs through the Health Policy PIA's busy week at AAIC, from PIA Day to a featured research session on dementia care across countries. Takeaways Policy is the bridge from the lab to the patient; without it, a breakthrough only reaches the few who can already afford care. Qualitative interviews and coding surface the right questions before the big quantitative money goes in. Caregivers matter enormously when someone with dementia meets the justice system, which raises the question of those who have none. AI and blood-based biomarkers carry legal and access questions, and the rules differ between, say, the US and Europe under GDPR. You do not join a PIA because you already belong; you belong because you get involved, and you need not be an expert to contribute. -- The Alzheimer’s Association International Society to Advance Alzheimer’s Research and Treatment (ISTAART) convenes the global Alzheimer’s and dementia science community. Members share knowledge, fuel collaboration and advance research to find more effective ways to detect, treat and prevent Alzheimer’s and other dementias. Professional Interest Areas (PIA) are an assembly of ISTAART members with common subspecialties or interests. There are currently 30 PIAs covering a wide range of interests and fields, from Neuroimaging to Diversity and Disparities and everything in between. Find out more at https://istaart.alz.org/ -- A transcript of this show, links and show notes and profile on all our guests are available on our website at https://www.dementiaresearcher.nihr.ac.uk. If you prefer to watch rather than listen, you will find a video version of this podcast on Apple Podcasts, YouTube, and on our website. Leave us a tip: https://dementia-researcher.captivate.fm/support Follow us on social media: https://www.instagram.com/dementia_researcher/ https://www.facebook.com/Dementia.Researcher/ https://www.twitter.com/demrescommunity https://www.linkedin.com/company/dementia-researcher https://bsky.app/profile/dementiaresearcher.bsky.social Download and Register with our Community App: https://www.onelink.to/dementiaresearcher We gratefully acknowledge the support of our funders: Alzheimer’s Association, Race Against Dementia, Alzheimer’s Research UK, Alzheimer’s Society, and the National Institute for Health and Care Research. The views and opinions expressed by guests in this podcast are their own and do not necessarily reflect those of the producers, funders, or sponsors. Subscribe to our sister show 'Dementia Researcher The Blogs': https://podfollow.com/dementia-researcher-blogs

    • Transcript
    • Chapters
  • #344
    June 29 · 36 min· Video

    Relay Podcast - Technology and Dementia PIA

    Welcome to the seventh season of the Dementia Researcher X ISTAART PIA Relay Podcast. Across six episodes, leading early career and senior researchers hand the mic from one ISTAART PIA to the next, giving you an honest, peer-to-peer tour of where dementia research is actually heading, from wearables and biomarkers to policy and trial design, in the run-up to AAIC. Sleep might be one of the earliest windows we have into brain health, and Dr Vanessa Young thinks the way we measure it is about to change. Fresh from finishing her PhD in May, Vanessa is a postdoc at the Glenn Biggs Institute and Communications Chair of the Technology and Dementia PIA. She studies sleep and the ageing brain, where the relationship seems to run both ways: as dementia develops, sleep gets worse, and poor sleep may feed back into the disease. With host Dr Carla Abdelnour, she gets into digital biomarkers, why wearables let you capture sleep continuously at home rather than in a one-off sleep study, and the move from wearables to "nearables", bed sensors and room radar that ask nothing of the participant at all. They also cover the analysis headache that comes with years of continuous data, the equity problem when a study needs home Wi-Fi, and what the PIA has planned for its full-day AAIC preconference on AI. Takeaways Sleep and dementia feed each other, so sleep is worth studying as somewhere we might actually step in and help. Wearables capture sleep night after night at home, which reaches people who live nowhere near a big sleep centre. The field is shifting from wearables to "nearables", sensors in the mattress or radar in the room, to cut participant burden and bias. Years of continuous data brings its own problem: telling meaningful signal apart from background noise. If a study needs Wi-Fi to send its data, it quietly excludes people, so digital equity has to be designed in. -- The Alzheimer’s Association International Society to Advance Alzheimer’s Research and Treatment (ISTAART) convenes the global Alzheimer’s and dementia science community. Members share knowledge, fuel collaboration and advance research to find more effective ways to detect, treat and prevent Alzheimer’s and other dementias. Professional Interest Areas (PIA) are an assembly of ISTAART members with common subspecialties or interests. There are currently 30 PIAs covering a wide range of interests and fields, from Neuroimaging to Diversity and Disparities and everything in between. Find out more at https://istaart.alz.org/ -- A transcript of this show, links and show notes and profile on all our guests are available on our website at https://www.dementiaresearcher.nihr.ac.uk. If you prefer to watch rather than listen, you will find a video version of this podcast on Apple Podcasts, YouTube, and on our website. Leave us a tip: https://dementia-researcher.captivate.fm/support Follow us on social media: https://www.instagram.com/dementia_researcher/ https://www.facebook.com/Dementia.Researcher/ https://www.twitter.com/demrescommunity https://www.linkedin.com/company/dementia-researcher https://bsky.app/profile/dementiaresearcher.bsky.social Download and Register with our Community App: https://www.onelink.to/dementiaresearcher We gratefully acknowledge the support of our funders: Alzheimer’s Association, Race Against Dementia, Alzheimer’s Research UK, Alzheimer’s Society, and the National Institute for Health and Care Research. The views and opinions expressed by guests in this podcast are their own and do not necessarily reflect those of the producers, funders, or sponsors. Subscribe to our sister show 'Dementia Researcher The Blogs': https://podfollow.com/dementia-researcher-blogs

    • Chapters
Showing 1–20 of 25 episodes